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Abstract  
(1) Background and Aims – Flow mediated dilatation of the brachial artery (FMD) is a 
biomarker of endothelial function and cardiovascular health. Impaired FMD is 
associated with several cardiovascular risk factors including hypertension and 
obesity. Various food ingredients such as polyphenols have been shown to improve 
FMD. We investigated whether consuming resveratrol, a polyphenol found in red 
wine, can enhance FMD acutely and whether there is a dose-response relationship 
for this effect.  
(2) Methods and Results – 19 overweight/obese (BMI 25-35 kg.m-2) men or post-
menopausal women with untreated borderline hypertension (systolic BP: 130-160 
mmHg or diastolic BP: 85-100 mmHg) consumed three doses of resveratrol 
(resVida™ 30, 90 and 270 mg) and a placebo at weekly intervals in a double-blind, 
randomized cross-over comparison. One hour after consumption of the supplement, 
plasma resveratrol and FMD were measured. Data were analyzed by linear 
regression versus log10 dose of resveratrol. 14 men and 5 women (age 55 ± 2 years, 
BMI 28.7 ± 0.5 kg.m-2, BP 141 ± 2 / 89 ± 1 mmHg) completed this study. There was 
a significant dose effect of resveratrol on plasma resveratrol concentration (P<0.001) 
and on FMD (P<0.01), which increased from 4.1 ± 0.8% (placebo) to 7.7 ± 1.5% after 
270mg resveratrol. FMD was also linearly related to log10 plasma resveratrol 
concentration (P<0.01). 
(3) Conclusion- Acute resveratrol consumption increased plasma resveratrol 
concentrations and FMD in a dose-related manner. This effect may contribute to the 
purported cardiovascular health benefits of grapes and red wine.  
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Introduction 
Impaired flow-mediated dilatation (FMD) in the brachial artery is characterised by 
loss of endothelium-dependent vascular smooth muscle relaxation in response to 
vasodilator stimuli (1). The resultant effect of this impairment may be partly due to 
alterations in the nitric oxide (NO) pathway, notably a reduction in endothelium-
derived NO bioavailability (2-3). Chronically reduced NO bioavailability could play a 
mechanistic role in the progression of cardiovascular disease (CVD) (2). In fact, 
impaired FMD is now recognised as an independent risk factor for the development 
of CVD (4-5). Several cardiovascular risk factors including hypertension (6) and 
overweight/obesity (7) are associated with impaired FMD, which may reflect 
structural and functional changes to the endothelium (8).  
Consumption of various polyphenol-rich food ingredients such as cocoa (9), green 
and black tea (10-11), grape seed extract (12) and red wine extract (13) have been 
shown to acutely improve FMD in at-risk population groups. However, it is not known 
which specific polyphenolic compounds present in these foods are responsible for 
this beneficial effect. Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenol 
predominately found in red wine and grapes that has attracted much interest due to 
its cardioprotective potential shown in vivo (14-16). Resveratrol exists in cis- and 
trans- isomeric forms, but only trans-isomer is mainly present in wine (17), which can 
be found at highest concentration in grape skin in ranges between 50 and 400µg/g of 
fresh weight (18). Hence, trans-resveratrol is often used in clinical trials due to its 
stability in absence of ultra-violet light (17). Depending on the variety of grape used 
in wine making, the concentration of trans-resveratrol in red wine is between 0.1 and 
14.0mg/L (19). The estimated daily intake of resveratrol in the United State of 
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America from naturally occurring sources is 0.08mg with 90th percentile consuming 
no more than 0.26mg daily (20).  
The purported cardiovascular benefits of resveratrol from experimental evidence 
include defence against ischaemic-reperfusion injury (21-23), suppression of platelet 
aggregation (16, 24), enhanced antioxidant status (16, 25) and increased NO 
bioavailability through enhanced endothelial NO synthase expression in cultured 
human endothelial cells (14-15). Recently, the progression of endothelial dysfunction 
and vascular remodelling in rats with pulmonary and cardiac abnormalities were 
slowed after three weeks of daily resveratrol administration (25mg/kg) (26). This 
cardioprotective effect was attributed to the actions of resveratrol in reducing 
vascular smooth muscle cell proliferation and enhancing endothelium-derived NO 
synthase and NO bioavailability.  
Thus, resveratrol supplementation may be able to enhance FMD in 
overweight/obese and/or hypertensive individuals in whom FMD may be impaired. 
To date, no human studies on the effects of pure resveratrol on FMD have been 
reported. Therefore, the objective of this study was to investigate whether oral 
resveratrol supplementation could acutely improve FMD in a dose-dependent 
manner.  
Methodology 
Study Design 
A randomised, double-blind, placebo-controlled, crossover human intervention trial 
comprising four visits at weekly intervals was undertaken. This study was approved 
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by the Human Research Ethics Committee of the University of South Australia. Each 
participant provided written and informed consent prior to participation.  
Study Population 
Overweight/obese (Body Mass Index [BMI] ≥ 25, <35 kg/m2) adults aged 30-70 
years with elevated blood pressure (BP) (systolic BP 130-160 mmHg and/or diastolic 
BP: 85-100 mmHg, determined at time of screening, were recruited for an acute 
dietary supplementation interventional trial. Sample size calculation indicated that 16 
volunteers were required to complete the study in order to provide 80% power to 
detect a difference in FMD of 2.0% at α of 0.05, based on an estimated standard 
deviation of 2.64% (9). 
Women were required to be post-menopausal (self reported cessation of menses for 
at least 12 months). An appropriately sized BP cuff was fitted to participants as they 
rested in a seated position for five minutes prior to BP assessment. Four readings 
were obtained with a SpaceLabs ambulatory BP monitor (Model 90217, SpaceLabs 
Medical, Florida, USA) at one-minute intervals with accordance to previously outlined 
procedures (27). Discarding the first reading, an average of the last three readings 
was used to determine BP eligibility. Volunteers had no history of CVD, diabetes or 
renal disease, were not taking diabetic or BP lowering medication and were not 
currently smoking or using nicotine replacement therapy. 
Participants were advised to maintain their customary diet prior to each visit, but to 
limit their polyphenol intake (including peanuts, cranberries, mulberries, red grapes, 
red wine, green tea and dark chocolate and physical activity habits throughout the 
study.  
Resveratrol Capsules 
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DNP-DSM Nutritional Products, Kaiseraugst, Switzerland, supplied all resveratrol 
(resVida™) and placebo capsules. Participants were allocated to consume each of 
three doses of resveratrol (30, 90 and 270mg) and a placebo at weekly intervals in a 
double-blind, randomized fashion. All doses consisted of six capsules and 
participants consumed a single dose once at each visit. The placebo capsules 
contained an inert filler consisting of Calcium Hydrogen Phosphate, microcrystalline 
cellulose of various particle sizes including Prosolv 50 and talcum powder (hydrated 
magnesium silicate), and were identical in appearance to the resveratrol capsules 
which contained 99% pure synthetic trans-resveratrol.  
Each dose of resveratrol was assigned the letters A, B, C and D by an independent 
staff member. A random number generator was used to determine the allocation of 
each dose to participants.  
Clinical Assessments 
Participants arrived at the research centre having fasted for at least four hours 
before consuming the six capsules with ad libitum water in the presence of an 
investigator (to ensure compliance). Outcome measures were then assessed after 
participants rested in the research centre for 45 minutes. This protocol was repeated 
a total of four times at weekly intervals, once for each resveratrol dose or placebo. 
No baseline treatment was given. 
FMD. Endothelial function was assessed using FMD by ultrasound (General Electric 
Logiq 5 Expert) with a two-dimensional B-mode 12 MHz transducer in accordance to 
published guidelines (28). Participants rested in a supine position for a further 15 
minutes before FMD testing commenced. This timing was chosen based on 
pharmacokinetic results of peak plasma resveratrol concentrations, which occurred 
0.8 to 1.5 hours after healthy subjects consumed a single dose of trans-resveratrol 
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(25-150mg) (29). Participants were fitted with an inflatable occlusion cuff, which was 
positioned on the right forearm abutting the cubital fossa to minimise movements in 
surrounding tissues when ultrasound images were collected. After obtaining an 
image of the brachial artery, 30 seconds of baseline data was recorded before the 
occlusion cuff was inflated to 200 mmHg for five minutes. Post-rapid deflation 
images of the brachial artery were recorded for a further three minutes. All recorded 
images were gated to end-diastole of the cardiac cycle for data analysis as 
determined by a single-lead electrocardiogram and digitally recorded onto a disc 
recorder hard drive (LG, LG Electronics, Eastern Creek, Australia). 
The FMD video files were analysed using the edge-detection software, Brachial 
Analyzer (Medical Imaging Application LLC, Iowa, United States). Each digitally 
recorded FMD file was converted to .AVI format using iSofter DVD ripper Platinum 
(iSofter Inc. 2005, United States) and separated into two files (baseline and 
deflation) for analysis. For both baseline and deflation, a region of interest was 
carefully defined over a clear section of vessel with care to ensure that the region of 
interest was the same size and position for both baseline and deflation files. The 
automated edge-detection feature of the software then performed a frame-by-frame 
analysis to generate artery diameter (mm) values for both baseline and deflation. 
Baseline was defined as the average of the 30 seconds of pre-inflation diameter 
measures. A spline curve was fitted through the deflation values and from this curve 
the peak diameter was determined. Using baseline and peak diameters, the percent 
change in diameter was calculated, which will hereby be referred to as %FMD.   
Plasma resveratrol concentration. Following FMD measurement, a venous blood 
sample was collected and centrifuged for 15 minutes at 1000g at 4ºC within 30 
minutes of blood sampling. Approximately 1mL of cell free plasma supernatant was 
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immediately transferred into a polypropylene Eppendorf tube, treated with nitrogen 
and stored at -80ºC freezer until analysis of plasma resveratrol concentrations.  
Liquid chromatography mass spectrometry (LC-MS) system was used to determine 
“free” trans-resveratrol, dihydroresveratrol (aglycone), “total” trans-resveratrol and 
dihydroresveratrol (aglycone plus glucuronide conjugates) in plasma samples. The 
samples were injected on a C18 column after adding internal standard and liquid-
liquid extraction (“free” analyte) or pre-digested by ß-glucuronidase followed by 
liquid-liquid (“total” analyte). Detection was performed using MS in the SIM mode.  
Statistical Analysis 
Statistical analyses were performed using SPSS Version 17 (Chicago, Illinois, United 
States of America). The 30, 90 and 270mg resveratrol doses and their corresponding 
plasma resveratrol concentrations were log transformed prior to analysis to give a 
linear dose progression. Linear regression analyses were performed for each 
outcome measure to determine the significance of the (a) dose-response relationship 
and (b) the differences between each dose of resveratrol and placebo. Adjustment 
was made for clustering due to repeated measures within a participant. Baseline 
brachial artery diameters for all doses were compared using one-way ANOVA. All 
results are presented as mean ± SEM.  
Results 
Subjects 
Participant flow is provided in Figure 1. Of the 20 participants who were enrolled, 19 
(14 males and 5 females) completed the study. One withdrew after one visit due to 
bronchitis, which required medication but was unrelated to participation in the study. 
Baseline characteristics are shown in Table 1.  
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Plasma resveratrol concentration 
With increasing doses of resveratrol, there were proportional increases in plasma 
resveratrol concentrations (ng/mL) (30mg: 181.31  13.59, 90mg: 532.00  86.38; 
270mg: 1232.16  147.57). Linear regression analysis revealed a significant 
relationship (P<0.001, R2=0.63) between log10 of resveratrol dose and log10 of 
plasma resveratrol concentration. There was also a significant linear relationship 
(P<0.01, R2=0.08) between log10 of plasma resveratrol concentration and acute FMD 
(Figure 2).  
FMD 
There was no significant difference (P=0.21) in the baseline brachial artery diameters 
measured following each dose (0mg: 4.25  0.17mm; 30mg: 4.08  0.15mm; 90mg: 
4.24  0.18mm; 270mg: 4.08  0.16mm). However, there was a significant linear 
relationship (P<0.01, R2=0.06) between log10 of resveratrol dose and acute FMD 
response. For each of the three doses of resveratrol (30, 90, 270mg), FMD was 
significantly increased (P<0.05) compared to placebo (Figure 3).  
 
Discussion 
This is the first study to evaluate the acute effects of resveratrol consumption on 
human circulatory function. Oral resveratrol supplementation elicited an acute dose-
related improvement in endothelium-dependent vasodilatation, as demonstrated by 
significant increases in FMD at each dose relative to the placebo. Improvements in 
FMD were correlated with a dose-related increase in plasma resveratrol 
concentrations. Whilst the FMD assessment does not reveal whether resveratrol is 
acting on the endothelium or on vascular smooth muscle to enhance vasodilatation, 
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there is evidence to suggest that resveratrol can increase endothelium-derived NO 
bioavailability (14, 30-31). Compared to placebo, our lowest dose (30mg) was shown 
to significantly improve FMD. A recent in vitro study (25) has shown that NO 
production could be enhanced in platelet cells of healthy adults after 15 days of 
moderate red wine consumption (300mL/day), which was associated with only a 
small amount of resveratrol (0.5μmol/L) in the plasma. However, other polyphenols 
present in the red wine may have contributed to the increased NO production. 
Similarly in a study by Lekakis et al. (13), significant improvements in FMD were 
observed 60 minutes after acute oral supplementation with 600mg of red wine 
polyphenol extract. Although trans-resveratrol was present in their extract, its low 
concentration of less than 1mg was unlikely to contribute significantly to the 
observed improvement in FMD. Other polyphenolic compounds such as epicatechin, 
which were present in higher concentrations in this extract may have mediated this 
improvement. Thus, the present study is the first to demonstrate that synthetic trans-
resveratrol can improve FMD acutely and in a dose-related manner in at-risk 
population groups. However, the lowest resveratrol dose (30mg) used in this study 
cannot be obtained from normal dietary habits (20). 
Whilst the acute improvement in FMD after supplementation is encouraging, it is 
important to see if this improvement seen in FMD after acute oral resveratrol 
supplementation is sustainable, given that little is known about the long-term effects 
of trans-resveratrol in human subjects following chronic supplementation.  
In conclusion, results of this acute study demonstrated a dose-related improvement 
in FMD that correlated with increased plasma resveratrol concentrations. FMD was 
significantly increased by each dose of resveratrol compared with placebo. These 
findings suggest that resveratrol may contribute to the purported cardiovascular 
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health benefits of grapes and red wine. Further research is warranted to confirm the 
sustainability of the effect of resveratrol on FMD.  
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Table 
Table 1 - Baseline characteristics of participants who completed the study. 
Number (Male/Female) 19 (14/5) 
Height (m) 1.76 ± 0.03 
Weight (kg) 88.7 ± 2.9 
BMI (kg.m-2) 28.7 ± 0.5 
Age (years) 55 ± 2 
SBP (mmHg) 141 ± 2 
DBP (mmHg) 89 ± 1 
HR (bpm) 69 ± 2 
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Figure legends 
Figure 1 - Consort diagram of participants who were screened, enrolled, completed 
the study and included in the analysis.  
Figure 2 – Individual FMD responses relative to log10 of plasma resveratrol 
concentration (P<0.01, R2=0.06). The solid line represents the mean of the slope.  
Figure 3 – FMD responses following consumption of each dose of resveratrol (mean 
± SEM). * = significant difference (P<0.05) relative to placebo. 
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Figures 
Figure 1 - Consort diagram of participants who were screened, enrolled, completed 
the study and included in the analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Withdrawal N=1 
 Work commitments (1) 
Excluded N=2 
 Fail exercise test (1) 
 Confirmed diabetes (1) 
Withdrawal N=1 
 Illness (1) 
FMD data 
Excluded N=1 
 Inconsistent images 
Invited for BP 
screening 
N=40 
Met BMI & BP criteria 
N=23 
Excluded N=15 
 BP too high (3) 
 BP too low (12) 
Withdrawal N=2 
 No show (2) 
Enrolled into study 
N=20 
FMD & plasma resveratrol 
concentration  
N=19 
Plasma resveratrol 
concentration 
included in 
analysis 
N=19 
FMD included in 
analysis 
N=18 
20 
 
Figure 2 – Individual FMD responses relative to log10 of plasma resveratrol 
concentration (P<0.01, R2=0.08). The solid line represents the mean of the slope.  
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 Figure 3 – FMD responses following consumption of each dose of resveratrol 
(mean ± SEM). * = significant difference (P<0.05) relative to placebo. 
 
 
